• H. pylori–HNF4A Silencing Drives Gastric Cancer

  2026-08-29

  A 2025 Cell Death and Disease study identifies promoter hypermethylation of HNF4A as a mechanistic link between Helicobacter pylori infection, epithelial polarity loss, EMT activation, and gastric cancer progression. Its integrated clinical, single-cell, cellular, and in vivo evidence positions HNF4A methylation as a testable axis in cancer epigenetics and gastric tumor biology.

• Amikacin Disulfate: From Ribosome to Assay Design

  2026-08-28

  Amikacin disulfate is a mechanistically informative 16S rRNA-targeting antibiotic for studying bacterial protein synthesis suppression and resistance. This article connects ribosome-centered assays with orthogonal protein-binding methods, showing how to separate molecular binding, structural change, and functional loss.

• Reparixin: From IL-8 Biology to Translational Proof

  2026-08-28

  A translational framework for using Reparixin, a CXCR1/2 inhibitor, to connect MRSA extracellular-vesicle signaling with tumor biology, neutrophil behavior, and tissue injury while maintaining clear experimental boundaries.

• Salinomycin: Measuring HCC Drug Response Precisely

  2026-08-28

  Salinomycin is a polyether ionophore antibiotic whose effects in hepatocellular carcinoma models require more than a single viability readout. This article presents an assay strategy that separates growth arrest, cell death, ion-homeostasis changes, and pathway modulation for more interpretable research conclusions.

• Carboplatin Workflows for DNA Damage Research

  2026-08-27

  Build reproducible Carboplatin dose–response, DNA synthesis, and resistance assays across ovarian, lung, and triple-negative breast cancer models. The workflow pairs practical formulation guidance with a mechanistic strategy for studying cancer stem-like cells and FZD1/7-linked resistance.

• DAPI and the Microbiome: From Nuclei to Translation

  2026-08-26

  The Prevotella copri–IPyA–UHRF1–AMPK axis reframes breast cancer progression as a microbiome-linked metabolic problem. DAPI adds a practical phenotypic layer, helping translational teams connect nuclear integrity, cell fate, and mechanistic pathway studies without overstating what a DNA stain can prove.

• Coelenterazine for Brain–Kidney Reporter Design

  2026-08-26

  Coelenterazine can do more than generate luciferase light: it helps researchers separate reporter activity, oxidative chemistry, and physiological outcome. This article develops an assay-design framework inspired by brain–kidney axis research and defines where ROS readouts are informative—and where they are not.

• Ridaforolimus in Cancer and Senescence Assays

  2026-08-26

  Ridaforolimus, also called Deforolimus or MK-8669, provides a precise way to interrogate mTOR-dependent growth, metabolism, VEGF output, and treatment response. This practical guide connects concentration-controlled cancer assays with machine-learning-inspired senescence workflows while emphasizing selectivity controls and troubleshooting.

• Palonosetron for Chemotherapy-Induced Nausea and Vomiting

  2026-08-25

  Ruhlmann and Herrstedt’s review explains why palonosetron became clinically distinctive among 5-HT3 receptor antagonists: it combines prolonged exposure and high receptor affinity with allosteric binding and positive cooperativity. The authors connect these pharmacologic properties with clinical evidence on acute and delayed chemotherapy-induced nausea and vomiting, while emphasizing that receptor-level differences matter only when they improve patient outcomes.

• Carboplatin Response: From Dose to Biology

  2026-08-24

  Carboplatin is a platinum-based DNA synthesis inhibitor whose apparent activity depends on both dose and cancer model architecture. This guide translates recent 2D-versus-3D proteomic findings into practical assay decisions for preclinical oncology research.

• PXR Activation, Liver Regeneration, and CYP Activity

  2026-08-24

  Bi et al. show that activating pregnane X receptor (PXR) in rats can couple liver enlargement and post-hepatectomy regeneration with increased activity of major drug-metabolizing CYP enzymes. By combining a partial-hepatectomy model, a CYP probe-drug cocktail, plasma pharmacokinetics, and hepatic protein analysis, the study distinguishes restoration of liver mass from functional changes in drug disposition.

• SM-102: A Decision Framework for mRNA LNPs

  2026-08-23

  SM-102 is more than an ionizable lipid ingredient: it is a useful test case for connecting chemical handling, LNP design, and assay interpretation. This evidence-driven guide explains how to evaluate SM-102 in mRNA delivery studies without overstating results from predictive models or single-animal comparisons.

• Epoxomicin Proteasome Inhibitor Workflow

  2026-08-22

  Epoxomicin provides a selective, irreversible way to interrogate proteasome-dependent protein turnover during ER stress and proteostasis failure. This practical guide connects dose design, degradation assays, UBR1/UBR2 biology, and troubleshooting for more reproducible ubiquitin-proteasome pathway research.

• Phytol Workflows for RXR Signaling Assays

  2026-08-21

  Build more reliable Phytol experiments by separating solvent, dose, isomer, and time effects across orthogonal readouts. This practical workflow connects RXR reporter assays with GABAergic and PPARα-focused studies while using the reference polymer study as a model for disciplined experimental design.

• YTHDF1–THBS1 Control of Osteogenesis under Hypoxia

  2026-08-20

  Shi and colleagues identify a compensatory YTHDF1–THBS1 pathway that supports osteogenic differentiation of MC3T3-E1 cells during hypoxia. Their experiments connect m6A-dependent RNA regulation with osteogenic markers, alkaline phosphatase activity, mineralization, and THBS1 transcript stability, providing a mechanistic framework for hypoxia-associated bone loss in peri-implantitis.

8558 records 1/571 page Next 12345 下5页 Last page